Literature DB >> 12354539

Promotion of lupus in NZB x NZWF1 mice by plasmids encoding interferon (IFN)-gamma but not by those encoding interleukin (IL)-4.

K Hasegawa1, T Hayashi, K Maeda.   

Abstract

The present study extended our previous observation that interferon (IFN)-gamma may be responsible for the active disease that develops in NZB x NZWF1 mice and serves as a model for human systemic lupus erythematosus. Treatments with cytokine-encoding plasmids were delivered intraperitoneally every 4 weeks, starting at 3 months of age (i.e. before the onset of lupus). In comparison with the control plasmid and the IL-4-encoding plasmid, the IFN-gamma-encoding plasmid promoted increased blood urea nitrogen values and reduced the survival rate, and these changes were accompanied by the development of anti-nuclear antibody. There were no differences, however, between treatment with control plasmids and treatment with IL-4-encoding plasmids in terms of the development of lupus. The findings clearly indicated that IFN-gamma but not IL-4 contributed to the development of lupus in the NZB x NZWF1 mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354539     DOI: 10.1053/jcpa.2002.0556

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  6 in total

1.  Polarization toward Th1-type response in active, but not in inactive, lupus inhibits late allergic rhinitis in lupus-prone female NZB×NZWF(1) mice.

Authors:  Toshiharu Hayashi; Ayumi Murase
Journal:  Inflammation       Date:  2012-12       Impact factor: 4.092

2.  The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.

Authors:  Lee Ann Garrett-Sinha; Alyssa Kearly; Anne B Satterthwaite
Journal:  Crit Rev Immunol       Date:  2016       Impact factor: 2.214

Review 3.  The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus.

Authors:  Laurie S Davis; Jack Hutcheson; Chandra Mohan
Journal:  J Interferon Cytokine Res       Date:  2011-07-25       Impact factor: 2.607

4.  Construction, purification, and characterization of a chimeric TH1 antagonist.

Authors:  Iraldo Bello-Rivero; Yeny Torrez-Ruiz; Elizabeth Blanco-Garcés; Giselle Pentón-Rol; Osmani Fernández-Batista; Luís Javier-González; Haydee Gerónimo-Perez; Pedro López-Saura
Journal:  BMC Biotechnol       Date:  2006-05-22       Impact factor: 2.563

5.  Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway.

Authors:  Li Huang; Yong Kong; Jing Wang; Jie Sun; Qin Shi; Yu-Hua Qiu
Journal:  Mol Med Rep       Date:  2015-06-18       Impact factor: 2.952

6.  Effect of bisphenol A on murine immune function: modulation of interferon-gamma, IgG2a, and disease symptoms in NZB X NZW F1 mice.

Authors:  Catherine Sawai; Katherine Anderson; Debby Walser-Kuntz
Journal:  Environ Health Perspect       Date:  2003-12       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.